The Common p.R114W HNF4A Mutation Causes a Distinct Clinical Subtype of Monogenic Diabetes
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
MR/M005070/1
Medical Research Council - United Kingdom
098395
Wellcome Trust - United Kingdom
MR/M501633/1
Medical Research Council - United Kingdom
RDECRF-2012-1
Department of Health - United Kingdom
MR/K007017/1
Medical Research Council - United Kingdom
PubMed
27486234
PubMed Central
PMC5035684
DOI
10.2337/db16-0628
PII: db16-0628
Knihovny.cz E-resources
- MeSH
- Diabetes Mellitus, Type 2 drug therapy genetics MeSH
- Adult MeSH
- Genetic Predisposition to Disease genetics MeSH
- Haplotypes genetics MeSH
- Hepatocyte Nuclear Factor 4 genetics MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation genetics MeSH
- Odds Ratio MeSH
- Birth Weight genetics physiology MeSH
- Aged MeSH
- Sulfonylurea Compounds therapeutic use MeSH
- Computational Biology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Hepatocyte Nuclear Factor 4 MeSH
- Hypoglycemic Agents MeSH
- Sulfonylurea Compounds MeSH
HNF4A mutations cause increased birth weight, transient neonatal hypoglycemia, and maturity onset diabetes of the young (MODY). The most frequently reported HNF4A mutation is p.R114W (previously p.R127W), but functional studies have shown inconsistent results; there is a lack of cosegregation in some pedigrees and an unexpectedly high frequency in public variant databases. We confirm that p.R114W is a pathogenic mutation with an odds ratio of 30.4 (95% CI 9.79-125, P = 2 × 10(-21)) for diabetes in our MODY cohort compared with control subjects. p.R114W heterozygotes did not have the increased birth weight of patients with other HNF4A mutations (3,476 g vs. 4,147 g, P = 0.0004), and fewer patients responded to sulfonylurea treatment (48% vs. 73%, P = 0.038). p.R114W has reduced penetrance; only 54% of heterozygotes developed diabetes by age 30 years compared with 71% for other HNF4A mutations. We redefine p.R114W as a pathogenic mutation that causes a distinct clinical subtype of HNF4A MODY with reduced penetrance, reduced sensitivity to sulfonylurea treatment, and no effect on birth weight. This has implications for diabetes treatment, management of pregnancy, and predictive testing of at-risk relatives. The increasing availability of large-scale sequence data is likely to reveal similar examples of rare, low-penetrance MODY mutations.
Institute of Biomedical and Clinical Science University of Exeter Exeter U K
Medical Research Institute Ninewells Hospital and Medical School University of Dundee Dundee U K
See more in PubMed
Yamagata K, et al. Mutations in the hepatocyte nuclear factor-4[alpha] gene in maturity-onset diabetes of the young (MODY1) Nature. 1996;384(6608):458–460. PubMed
Pearson ER, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4):e118. PubMed PMC
Shields BM, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508. PubMed
Furuta H, et al. Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. Diabetes. 1997;46(10):1652–1657. PubMed
Delvecchio M, et al. Low prevalence of HNF1A mutations after molecular screening of multiple MODY genes in 58 Italian families recruited in the pediatric or adult diabetes clinic from a single Italian hospital. Diabetes Care. 2014;37(12):e258–260. PubMed
Ludovico O, et al. Identification and Clinical Characterization of Adult Patients with Multigenerational Diabetes Mellitus. PLoS One. 2015;10(8):e0135855. PubMed PMC
Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. bioRxiv. 2015 PubMed PMC
Shankar RK, et al. Digenic heterozygous HNF1A and HNF4A mutations in two siblings with childhood-onset diabetes. Pediatr Diabetes. 2013;14(7):535–538. PubMed PMC
Navas M, et al. Functional characterization of the MODY1 gene mutations HNF4(R127W), HNF4(V255M), and HNF4(E276Q) Diabetes. 1999;48(7):1459–1465. PubMed
Yang Q, et al. R127W-HNF-4alpha is a loss of function mutation but not a rare polymorphism and causes Type II diabetes in a Japanese family with MODY1. Diabetologia. 43:520–524. PubMed
Lausen J, et al. Naturally occurring mutations in the human HNF4α gene impair the function of the transcription factor to a varying degree. Nucleic Acids Research. 2000;28(2):430–437. PubMed PMC
Yaghootkar H, et al. Association Analysis of 29,956 Individuals Confirms That a Low-Frequency Variant at CCND2 Halves the Risk of Type 2 Diabetes by Enhancing Insulin Secretion. Diabetes. 2015;64(6):2279–2285. PubMed PMC
Wiltshire S, et al. A Genomewide Scan for Loci Predisposing to Type 2 Diabetes in a U.K. Population (The Diabetes UK Warren 2 Repository): Analysis of 573 Pedigrees Provides Independent Replication of a Susceptibility Locus on Chromosome 1q. American Journal of Human Genetics. 2001;69(3):553–569. PubMed PMC
Frayling TM, et al. Parent-offspring trios: a resource to facilitate the identification of type 2 diabetes genes. Diabetes. 1999;48(12):2475–2479. PubMed
Consortium, T.W.T.C.C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–678. PubMed PMC
Knight B, Shields BM, Hattersley AT. The Exeter Family Study of Childhood Health (EFSOCH): study protocol and methodology. Paediatric and Perinatal Epidemiology. 2006;20(2):172–179. PubMed
Dusatkova P, et al. Ancestral mutations may cause a significant proportion of GCK-MODY. Pediatric Diabetes. 2012;13(6):489–498. PubMed
Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Statistics in Medicine. 1998;17(4):407–429. PubMed
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research. 2010;38(16):e164. PubMed PMC
Chandra V, et al. Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex. Nature. 2013;495(7441):394–398. PubMed PMC
Hegele RA, et al. The Hepatic Nuclear Factor-1α G319S Variant Is Associated with Early-Onset Type 2 Diabetes in Canadian Oji-Cree. The Journal of Clinical Endocrinology & Metabolism. 1999;84(3):1077–1082. PubMed
Harries LW, et al. Diabetes Susceptibility in the Canadian Oji-Cree Population Is Moderated by Abnormal mRNA Processing of HNF1A G319S Transcripts. Diabetes. 2008;57(7):1978–1982. PubMed PMC
Estrada K, et al. Association of a Low-Frequency Variant in HNF1A With Type 2 Diabetes in a Latino Population. JAMA. 2014;311(22):2305–2314. PubMed PMC
Jafar-Mohammadi B, et al. A role for coding functional variants in HNF4A in Type 2 Diabetes susceptibility. Diabetologia. 2011;54(1):111–119. PubMed PMC
Hamilton AJ, et al. The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a beta cell phenotype. J Med Genet. 2014;51(3):165–9. PubMed PMC
The Genomes Project, C. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. PubMed PMC
Colclough K, et al. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Human mutation. 2013;34(5):669–685. PubMed